slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 227,281-227,310
Pages 10,126
Rows per page 30
Component
227,281-227,310 of 303,780
17
The table highlights a heavily pretreated population, with 77% having received 3 or more prior lines of therapy and 71% having received 2 or more prior ROS1 TKIs.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
18
Data as of 13 Sep 22. N=35 patients.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
19
The chart displays dose-dependent exposure levels exceeding multiple efficacy thresholds for ROS1 variants in CNS and peripheral tissues.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
20
Clinical trial data table showing efficacy metrics for NVL-520 in NSCLC patients.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
21
The chart uses a waterfall plot to visualize clinical efficacy, a standard in oncology drug development.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
22
The chart is a swimmer plot, commonly used in oncology to visualize time-to-event data for individual patients.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
23
Includes a spider plot (target lesion change) and a bar chart (allele clearance).Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
24
Includes specific patient case study (65-year-old female) and aggregate clinical trial data.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
25
The slide uses a timeline-style list on the left to show treatment history and a visual 'before-and-after' comparison of medical imaging on the right.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations 1 hit
27
The slide uses a process flow to show the evolution of data from preliminary Phase 1 to updated data shared with the FDA.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations 1 hit
32
Shows superior potency and efficacy against resistant mutations compared to standard-of-care inhibitors like Lorlatinib.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Loop · Jobs To Be Done1 hit
33
The slide uses a bar chart for brain penetrance and a scatter plot for selectivity index to demonstrate the drug's therapeutic profile.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Loop · Jobs To Be Done1 hit
34
Clinical trial design slide detailing patient population, objectives, and cohort structure.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Loop · Jobs To Be Done1 hit
35
BOIN stands for Bayesian Optimal Interval design.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Loop · Jobs To Be Done1 hit
36
Clinical trial baseline characteristics table.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Loop · Jobs To Be Done1 hit
37
Data cut-off: 8 Aug 2023. Includes detailed footnotes regarding specific patient events.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Loop · Jobs To Be Done1 hit
38
The chart displays a line graph with error bars representing standard deviation for five different dosage cohorts (15mg to 150mg QD).Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Loop · Jobs To Be Done1 hit
39
The chart displays patient-level data categorized by dose and mutation type, highlighting the efficacy of NVL-655 in clearing specific ALK resistance mutations.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Loop · Jobs To Be Done1 hit
40
Data cut-off: 8 Aug 2023. Source: Lin J.J. et al., AACR-NCI-EORTC 2023.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Loop · Jobs To Be Done1 hit
41
The slide uses a split waterfall plot to compare two patient cohorts. It includes a detailed data table below the chart showing dose levels and prior treatment history.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations 1 hit
42
The chart is a swimmer plot, commonly used in oncology clinical trials to visualize time-to-event data.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations 1 hit
43
The slide presents two patient case studies with MRI scans showing tumor reduction.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations 1 hit
44
Includes clinical data points for EML4-ALK v3, G1202R, G1269A, and I1322M.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations 1 hit
47
The slide uses three distinct chart types to demonstrate efficacy, selectivity, and pharmacokinetics.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations 1 hit
48
Nuvalent | Investor Presentation Deck | 52 slidesNuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations 1 hit
50
The slide uses a Gantt-chart style visualization to show the progress of three specific drug candidates (NVL-520, NVL-655, NVL-330) through clinical development phases.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations 1 hit
02
Oatly | Results Presentation Deck | 39 slidesOatly | Results Presentation Deck | 39 slides · Oatly
Conference presentation Investor relations Beat · Attention1 hit
03
Oatly | Results Presentation Deck | 39 slidesOatly | Results Presentation Deck | 39 slides · Oatly
Conference presentation Investor relations Beat · Attention1 hit
04
Oatly | Results Presentation Deck | 39 slidesOatly | Results Presentation Deck | 39 slides · Oatly
Conference presentation Investor relations Beat · Attention1 hit
05
Uses leaf icons as bullet points; includes a footnote regarding non-IFRS measures.Oatly | Results Presentation Deck | 39 slides · Oatly
Conference presentation Investor relations Beat · Attention1 hit